Innovative Patient-partner-guided Virtual Group Speech Pathology Intervention Model in Head and Neck Cancer
NCT05621889
Summary
This project aims to study an innovative intervention, the eG2 Intervention, developed by speech-language pathologists at the Centre hospitalier de l'Université de Montréal to improve therapeutic adherence and prevent dysphagia in patients treated with chemoradiotherapy for head and neck cancer. The innovation consists in offering a speech therapy intervention that is 1) virtual, 2) group-based (whereas it is usually individual) and 3) involves a patient partner. This intervention has the potential to improve quality of care, accessibility to services and optimize health care resources.
Eligibility
Inclusion Criteria: * Adults ≥ 18 years of age with a diagnosis of head or neck cancer * Chemoradiotherapy treatments planned for curative purposes * Planned external radiation therapy dose of at least ≥60 Grays * Sufficient proficiency in French to complete self-reported questionnaires Exclusion Criteria: * Remote metastases * Previous or planned total laryngectomy * Previous moderate/severe dysphagia known and/or evaluated by speech therapy * Diagnosis of a second synchronous cancer at the time of study enrollment * History of prior radiation therapy to the head and neck area * Have a cognitive impairment (diagnosed or suspected) that may significantly interfere with participation in the intervention and various measurement procedures.
Conditions2
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT05621889